Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28822001 | 0.96 | MMP8 (0.37) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL793641 | 0.90 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL1564401 | 0.86 | CPA1 (0.40) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| Butane SCHEMBL18797012 | 0.86 | TSHR (0.39) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL4766772 | 0.84 | TSHR (0.42) | ALDH1A1HSD17B10TSHRGAATDP1 | |
| Ethyl Acetate SCHEMBL28822004 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10NPSR1GLO1 | |
| SCHEMBL19284346 | 0.82 | SOAT1 (0.37) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL27863535 | 0.82 | TSHR (0.44) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL6664974 | 0.82 | L3MBTL1 (0.39) | ALDH1A1LMNAHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL15218038 | 0.82 | TSHR (0.50) | ALDH1A1L3MBTL1NPSR1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118688344-A | Gas phase detection method for twelve impurities in pentoxifylline starting material (5, 6-dihydro-3-ethoxycarbonyl-2-methyl-4H-pyran) | 常州制药厂有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-102060754-A | Method for preparing polysubstituted tetrahydropyridine | UNIV NORTHWEST NORMAL | 2011-05-18 | — | — | CN | claimed |
| WO-2003082821-A1 | PROCESS FOR PRODUCING 2,6-DIHYDROXY-3,4-DIALKYLPYRIDINES | ISP INVESTMENTS INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-6624307-B1 | Reacting 2-cyanoacetamide with sodium methoxide; condensation with ethyl 2-methylacetoacetate in methanol; salt formation to 2,6-dihdroxy-4,5-dimethyl-3-pyridinecabonitrile; hydrolysis, decarboxylation | ISP INVESTMENTS INC. | 2003-09-23 | — | — | US | claimed |
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2025-05-15 | — | — | US | disclosed |
| CN-118688344-A | Gas phase detection method for twelve impurities in pentoxifylline starting material (5, 6-dihydro-3-ethoxycarbonyl-2-methyl-4H-pyran) | 常州制药厂有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4029857-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2022-07-20 | — | — | EP | disclosed |
| EP-3365329-B1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2022-03-30 | — | — | EP | disclosed |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2021-06-24 | — | — | US | disclosed |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | VASSILATIS DEMETRIOS K (GR) | 2021-03-16 | — | — | US | disclosed |
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| WO-1993008169-A1 | SUBSTITUTED AMINOPYRIMIDINES AS ANGIOTENSINE II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-04-29 | — | — | WO | disclosed |
| US-4551457-A | GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1985-11-05 | — | — | US | disclosed |
| US-4444773-A | ANTIULCER, ANTISECRETORY, ANTIINFLAMMATORY | FARMITALIA CARLO ERBA S.P.A. (IT) | 1984-04-24 | — | — | US | disclosed |
| US-4245122-A | USING TRICAPRYLMETHYLAMMONIUM CHLORIDE AS A PHASE TRANSFER AGENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-01-13 | — | — | US | disclosed |
| US-4081596-A | DIURETIC, SALURETIC, ANTIHYPERTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-28 | — | — | US | disclosed |
| US-4005215-A | DIURETIC | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-25 | — | — | US | disclosed |
| US-3978077-A | DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (GB) | 1976-08-31 | — | — | US | disclosed |
| US-3957814-A | DIURETICS, SALURETICS, HYPOTENSIVE AGENTS, ANTITHROMBOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NCOR1 | ALDH1A1 1790/4885LMNA 4531/4885HSD17B10 2860/4885 |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | ALDH1A1 1716/4885LMNA 4486/4885HSD17B10 2977/4885 |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | NR4A2, NR0B1, NR4A3 | ALDH1A1 1716/4885LMNA 4486/4885HSD17B10 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.